March 3, 2026
Increased serum antibody response to commensal Lachnospiraceae flagellins appears to be preclinically associated with future risk for Crohn’s disease (CD) in healthy first-degree relatives (FDRs) of […]
March 2, 2026
Nausea. Constipation. Diarrhea. Heartburn. These are the annoying side effects that GLP-1 users complain about most often — and sometimes prompt them to discontinue the medications. […]
March 2, 2026
In patients with unexplained acute recurrent pancreatitis who have pancreas divisum, the widely used procedure endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy does not reduce the […]
February 27, 2026
TOPLINE: Among adults with obesity and type 2 diabetes (T2D), metabolic and bariatric surgery reduced the risk for major adverse cardiovascular events by more than 50% […]
February 27, 2026
TOPLINE: Among patients with Crohn’s disease, risankizumab yielded significant improvements in clinical and endoscopic outcomes and had a favourable safety profile; prior ustekinumab exposure was associated […]
February 27, 2026
TOPLINE: A withdrawal time of 3 minutes or longer in the proximal colon during screening colonoscopy was associated with higher rates of detection of proximal and […]
February 27, 2026
Breakfast meals higher in protein promoted feelings of satiety, and those higher in fiber boosted beneficial gut microbiota, while both types led to weight loss and […]
February 27, 2026
GLP-1s are associated with an array of possible side effects that contribute to medication nonadherence and discontinuation among a significant portion of users, although most patients […]
February 26, 2026
TOPLINE: Age-adjusted rates of cardiovascular disease (CVD) mortality tripled from 3.4 to 10.34 per 100,000 people between 1999 and 2023 among US adults with obesity, with […]